Otsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) recently announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease […]
Polpharma Biologics and Tuteur Sign Biosimilar Licensing Deal
Polpharma Biologics, one of the leading biopharmaceutical companies specialising in the development and manufacturing of biosimilars, announced on May 22nd the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialise a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will […]
MTF Biologics and Centurion partner to advance wound care technologies
MTF Biologics, a global leader in tissue-based solutions, and Centurion Therapeutics, a pioneering distributor in the medical field, yesterday announced they have entered into a new agreement that will give more clinicians and patients in complex wound settings within hospitals and post-acute care facilities access to advanced wound healing technologies. The agreement, which is an expansion […]